# The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain

> **NCT05542381** · NA · COMPLETED · sponsor: **Virginia Polytechnic Institute and State University** · enrollment: 64 (actual)

## Conditions studied

- Age-Related Macular Degeneration

## Interventions

- **DRUG:** Loteprednol Etabonate Ophthalmic Gel [Lotemax]
- **OTHER:** Refresh Lubricant Eye Drops [Artificial Tears]

## Key facts

- **NCT ID:** NCT05542381
- **Lead sponsor:** Virginia Polytechnic Institute and State University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-22
- **Primary completion:** 2024-05-01
- **Final completion:** 2025-05-01
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2025-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05542381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05542381, "The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05542381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*